Linda Richardson - Intercept Pharmaceuticals Ex Officer
Insider
Linda Richardson is Ex Officer of Intercept Pharmaceuticals
| Age | 59 |
| Phone | 646 747 1000 |
| Web | https://www.interceptpharma.com |
Intercept Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0723) % which means that it has lost $0.0723 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6402) %, meaning that it created substantial loss on money invested by shareholders. Intercept Pharmaceuticals' management efficiency ratios could be used to measure how well Intercept Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Intercept Pharmaceuticals currently holds 332.67 M in liabilities with Debt to Equity (D/E) ratio of 411.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intercept Pharmaceuticals has a current ratio of 3.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Intercept Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 61 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Michael Esq | TG Therapeutics | 59 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Brian Sullivan | Elevation Oncology | N/A | |
| CPA CPA | TG Therapeutics | 42 | |
| MBA IV | Enveric Biosciences | 68 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| David Glynn | Krystal Biotech | N/A | |
| MS MBA | Krystal Biotech | 60 | |
| David Dornan | Elevation Oncology | 47 | |
| William JD | Akero Therapeutics | 51 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Valerie MD | Elevation Oncology | 46 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 |
Intercept Pharmaceuticals Leadership Team
Elected by the shareholders, the Intercept Pharmaceuticals' board of directors comprises two types of representatives: Intercept Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intercept. The board's role is to monitor Intercept Pharmaceuticals' management team and ensure that shareholders' interests are well served. Intercept Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intercept Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Richardson, Ex Officer | ||
| Andrew Saik, Chief Officer | ||
| David Ford, Chief Human Resource Officer | ||
| Jerome Durso, CEO Pres | ||
| Mark MD, Advisor Founder | ||
| Jared JD, G Counsel | ||
| Rocco Venezia, Chief Treasurer | ||
| Paul Nitschmann, VP Affairs | ||
| Nareg Sagherian, Ex Relations | ||
| MD MPH, Pres Officer |
Intercept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intercept Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.0723 | |||
| Profit Margin | (0.19) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 695.84 M | |||
| Shares Outstanding | 41.81 M | |||
| Shares Owned By Insiders | 3.12 % | |||
| Shares Owned By Institutions | 81.30 % | |||
| Number Of Shares Shorted | 10.19 M | |||
| Price To Earning | (3.88) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |